A large number of pharmaceutical companies have successfully financed funds, which will accelerate product innovation and commercialization

【Pharmaceutical Network Industry News】Under the background of increasingly strict and standardized regulatory policies in China's pharmaceutical industry, increasingly fierce competition environment, rising costs of new drug research and development, and traditional pharmaceutical enterprises are under increasing growth pressure, the financing of the pharmaceutical circle has continued to be hot
in recent years.
According to data, from January to August 2022, a total of 1,026 financing events occurred in the national biomedical industry, with a cumulative amount of 89.
174 billion yuan
.
Recently, a number of pharmaceutical companies have announced the completion of financing, clearly accelerating product innovation and commercialization
.
For example, a few days ago, Beijing Kerui Biotechnology Co.
, Ltd.
(hereinafter referred to as "Kerui Biotechnology") completed a 100-million-level Pre-A+ round of financing, which was jointly led by Sunshine Fusion and Xinrui Medical, and followed by Longmen Capital
.
This round of financing will be used to advance multiple innovative TCR-T cell therapy products and soluble TCR protein drug development pipelines, including cell therapy products targeting KRAS-G12 mutations and global innovative TCR protein drugs
targeting KRAS-G12 mutations.
Recently, Zhuhai Beihai Biotechnology Co.
, Ltd.
(hereinafter referred to as "Beihai Biotechnology") also announced the completion of nearly 200 million yuan of Series B financing
.
This round of financing was led by Yikai Venture Capital, with additional investment from the old shareholder Guozhong Capital, followed by investors such as Yuanhe Chenkun Jingu Capital, Qingdao Hongteng and Jinhang Investment
.
This round of financing funds will be used for the clinical development of the company's core products, the listing application of the first blockbuster variety BH009 and the expansion of
the team.
From the perspective of this year's popular investment track, in the primary market, cell therapy, macromolecular innovative drugs, gene therapy and other subdivisions in the field of innovative drugs are still favored
.
Among them, the cell therapy track has attracted much attention
from capital.
Gene therapy is a new generation of precision therapy after small molecule and large molecule targeted therapy, providing new treatment concepts and means for tumors, rare diseases, chronic diseases and other refractory diseases, with considerable market prospects, which has increased from $50 million in 2016 to $2.
075 billion in 2020, with an average annual compound growth rate of nearly 154%, and is expected to reach nearly $6.
6 billion
in 2022.
In recent years, cell and gene therapy has become one of the most eye-catching emerging areas in the global biotechnology field, and as a result, it continues to receive significant investment
from investors and biopharmaceutical companies.
Data shows that from 2016 to 2020, the total financing of the global gene therapy industry has increased significantly from $5.
22 billion to $19.
9 billion, with an average annual compound growth rate of nearly 40%.

In general, although the popularity of the financing market has declined as a whole this year, new first-tier and second-tier cities are favored by capital; In addition, the investment and financing trend in the medical and health field is still optimistic about the industry
.
The industry expects that in the future, driven by both policy and interests, more investors will focus on innovative research and development and cutting-edge technologies with original innovation attributes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.